Dr Agarwal's HeaQ1 FY27
Dr Agarwal's Hea Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹500P/E: 107.4Market Cap: ₹15.9K CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- →Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each).
- →Same-store sales growth (SSSG) for mature facilities (pre-FY23) was strong at 16.3%, with new centers showing even higher growth.
- →Patient volume growth expected to continue, supported by technology upgrades and insurance expansion.
- →Premiumization and price hikes contributed ~8% to value growth.
- →Expansion of network with 60 new facilities planned for FY27 (40 surgical centers), maintaining aggressive greenfield growth.
- →Increasing adoption of advanced, higher-margin surgical procedures like Femto cataract and robotic surgeries expected to boost average realization per surgery.
- →Focus on deeper market penetration, especially in mature South region; North and West regions showing significant growth opportunities.
- →Merge completion expected by mid-November 2026, supporting operational synergies and growth momentum.
- →Overall outlook remains positive with sustained volume and revenue growth anticipated.
Margin guidance
Category 3- →Q1 FY27 showed strong revenue growth of 26% YoY and Ind AS EBITDA growth of 25.2% with margin improvement.
- →PAT margin expanded by 127 basis points to 8.9%, despite rising greenfield losses from new surgical facilities.
- →Management expects sustained growth momentum fueled by deeper penetration in existing micro markets, geographic expansion, and accelerated adoption of innovative surgical procedures and technologies.
- →Addition of 60 new facilities planned for FY27 including 40 surgical centers, with a strong pipeline of 30+ LOIs showing continued expansion.
- →Improvement in gross margin (~1% YoY) and reduction in finance costs due to lower interest on deferred acquisition payables expected to support profits.
- →Increasing mature centers with healthy same-store sales growth (12-16%) and premiumization will favor operating profitability.
- →Operational efficiency and disciplined execution will underpin sustained EBITDA and profit growth.
- →Merger completion expected by mid-November, possibly enhancing scale and earnings further.
3 more insights locked — sign up free to unlock
Fundraise plans
- →The transcript does not explicitly mention any current or planned fundraising through debt or equity.
- →The company highlighted a reduction in finance costs due to repayment of about INR 25 crores on deferred acquisition payable in Q1 FY27.
- →Finance cost decreased from INR 24.7 crores in Q1 last year to INR 23.5 crores in Q1 FY27, partly due to interest savings on deferred acquisition payments.
- →The focus appears to be on strong organic growth through expansion of facilities and improving operational efficiencies.
- →There were no direct disclosures or plans regarding fresh debt or equity fundraising in the Q1 FY27 earnings call.
Order book
- →The transcript does not explicitly mention the current or expected order book or pending orders.
- →However, it states a strong pipeline of greenfield projects with "30-plus signed Letters of Intent (LOIs)" already in place.
- →The company plans to add 60 new facilities in FY27, including 40 surgical centers.
- →Expansion plans include adding 12 facilities in Q2 and 30 in the second half of the year.
- →The greenfield execution engine is described as "firing" with strong pipeline and signed agreements, indicating robust upcoming projects and orders.
- →No specific order book value or financial quantification of pending orders is provided.
Capex plans
Yes- →Dr. Agarwal's Healthcare continues a strong expansion strategy with a large capital investment in greenfield facilities.
- →In Q1 FY27 alone, 18 new greenfield facilities were commissioned, including 1 large tertiary and 15 secondary facilities across various states.
- →The company plans to add 60 new facilities in FY27, including 40 surgical centers, with 12 facilities targeted for Q2 and 30 in the latter half of the year.
- →There is a strong pipeline with 30+ signed Letters of Intent (LOIs) for upcoming greenfield projects.
- →Expansion focuses on geographic diversification and deepening market penetration, including significant growth in Delhi NCR region with 8 facilities currently and 3 to 5 more planned within the year.
- →Ongoing investment in advanced surgical technology and innovative procedures continues to drive strategic clinical excellence.
How does Dr Agarwal's Hea rank vs peers in Healthcare Services?
Pro feature1Dr Agarwal's Hea
Rev 2Mar 3
See full Healthcare Services sector rankings
How does Dr Agarwal's Hea rank in Healthcare Services?
Compare Dr Agarwal's Hea against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.